# OnCo record kumquat-biosciences (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kumquat-biosciences/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kumquat-biosciences" ;
  schema:name "Kumquat Biosciences"@en ;
  schema:description "Kumquat Biosciences is a San Diego company founded by KRAS pioneers that makes pills against the KRAS cancer protein and immune-boosting small molecules. Its KRAS G12D drug entered human trials with Bayer in 2025."@en ;
  schema:url <https://onco.cc/companies/kumquat-biosciences/>, <https://kumquatbiosciences.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://kumquatbiosciences.com/>, <https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-enter-global-exclusive-license-and-collaboration-in-precision-oncology/>, <https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-initiate-phase-i-study-with-kras-g12d-inhibitor-in-patients-with-kras-mutated-tumors/>, <https://kumquatbiosciences.com/news/kumquat-biosciences-and-takeda-enter-into-strategic-collaboration-and-exclusive-global-license-agreement-to-advance-novel-oral-immuno-oncology-drug-candidate/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:trials <https://onco.cc/trials/nct07406633/> .